US5534527A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for inhibiting bone loss by treating with aroylbenzothiophenes and estrogen
Assignee: Eli Lilly and Co
•
Filing: 1995-04-14
•
Granted: 1996-07-09
•
Expires: 2015-04-14
Abstract
Abstract The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
Inventors
- 👤 Larry J. Black
- 👤 George J. Cullinan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:37
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/38; A61K31/381; A61K31/395; A61K31/40; A61K31/4025; A61K31/41; A61K31/425; A61K31/435; A61K31/44; A61K31/445; A61K31/4523; A61K31/453; A61K31/4535; A61K31/55; A61K31/56; A61K9/00; A61K9/0087; A61K9/0095; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054; A61K9/2059; A61K9/48; A61K9/4841; A61K9/4866; A61P; A61P19/00; A61P19/08; A61P19/10; A61P43/00; A61P5/00; A61P5/24; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
125 words
A pharmaceutical formulation comprising an effective amount of a compound of formula I ##STR11## wherein X is a bond, CH 2 , or CH 2 CH 2 ; R and R 1 , independently, are hydrogen, hydroxyl, C 1 -C 6 -alkoxy, C 1 -C 6 -acyloxy, C 1 -C 6 -alkoxy-C 2 -C 6 -acyloxy, R 3 -substituted aryloxy, R 3 -substituted aroyloxy, R 4 -substituted carbonyloxy, chloro, or bromo; R 2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino; R 3 is C 1 -C 3 -alkyl, C 1-C 3 -alkoxy, hydrogen, or halo; and R 4 is C 1 -C 6 -alkoxy or aryloxy; or a pharmaceutically acceptable salt thereof; estrogen and a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
125 words
A pharmaceutical formulation comprising an effective amount of a compound of formula I ##STR11## wherein X is a bond, CH 2 , or CH 2 CH 2 ; R and R 1 , independently, are hydrogen, hydroxyl, C 1 -C 6 -alkoxy, C 1 -C 6 -acyloxy, C 1 -C 6 -alkoxy-C 2 -C 6 -acyloxy, R 3 -substituted aryloxy, R 3 -substituted aroyloxy, R 4 -substituted carbonyloxy, chloro, or bromo; R 2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino; R 3 is C 1 -C 3 -alkyl, C 1-C 3 -alkoxy, hydrogen, or halo; and R 4 is C 1 -C 6 -alkoxy or aryloxy; or a pharmaceutically acceptable salt thereof; estrogen and a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US4133814A
Cited
US4185108A
Cited
US4418068A
Cited
EP0068563A2
Cited
US4729999A
Cited
US4894373A
Cited
US4970237A
Cited
US5118667A
Cited
US5393763A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-07-09 | 2000-01-08 | 2000-07-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-07-09 | 2004-01-08 | 2004-07-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-07-09 | 2008-01-08 | 2008-07-09 | $7700.00 | Window Closed / Lapsed |